Branching Out With EndeavorRx

When the “digital therapeutic device” EndeavorRx was just a twinkle in its originator’s eye, it went by the code name of AKL-T01. The initial goal was to help children afflicted by attention-deficit/hyperactivity disorder (ADHD) — but, hopefully, not that group exclusively.

There are certain maladies which, as a general rule, a given individual can be fairly certain he or she will never need to fear. But because life is unfair, certain groups, either intrinsically or due to several variables, are sometimes prone to afflictions that others rarely or never face. Both psychological therapy and pharmaceuticals — to name but two curative modes — are very often useful in treating misfortunes that strike people of various ages, genders, body types, nationalities, races, and so on.

Those facts constitute a portion of one of the issues that AKL-T01 originally set out to address. A big question was, if this thing worked for the initial target group, would it be generalizable? Could it affect lots of people in a positive way? Might it be useful in as-yet-unguessed ways, to individuals of various ages, genders, builds, countries of origin, etc.?

But wait, there is more…

The other high-priority question was whether the effects of using the new invention would prove to be durable. After much investment of time, money, faith, and other tangible and intangible contributions, would EndeavorRx actually help the kids who used it to get better, and not have to live under the rule of their ADHD? If the technique helped at all, would it continue to be useful, or would it somehow “wear off”?

With any problem, whether the chosen solution is a pair of shoes or an entire philosophy of life, durability is a requirement. This thing that helps us to fill our needs — will it still do its job next week and next year? Once we master effective use of it, the tool needs to be reliable, and as close to unbreakable as possible.

Altogether, it was deemed reasonable to put faith in the viability of a digital therapeutic device. Once that philosophical commitment has been made, would it not be reasonable to hope that, as time passed, new and promising uses would be found for it?

If it could affect ADHD, could it improve the grades on report cards? Could it help a reckless child become more safety-conscious? Maybe it could even help to minimize sleepwalking, or curb an insatiable appetite. New discoveries often arrive in the form of answers that previously would have seemed illogical or impossible.

In the early days

Generalizability, durability, and, of course, “continued examination of the extent of treatment effects” — all of these separate strands of investigation were closely watched. As reported in a 2021 paper,

[C]ontinued evaluation of the effects of AKL-T01 on other important aspects of functioning like academic and social functioning, health utilization and health outcomes would continue to add to the evidence base that the effects observed in this and previous studies have substantial clinical and functional impact.

It is doubtful whether anyone really got excited about this aspect at the time, but the mention of “health utilization and health outcomes” might have stirred some hopes regarding an area that no one had previously thought to connect with this therapeutic modality — the messy world of eating disorders.

A 2021 article by Kezia Parkins, the lead editor for Medical Device Network and Medical Technology Magazine, mentioned more facets of the early trials and observations, and quoted Akili Interactive CEO Dr. Eddie Martucci, who explained how the experimental device could…

[…] deliver the stimuli that engage targeted neural systems in the prefrontal cortex by forcing the brain to manage multiple streams of information simultaneously in an environment of ever-increasing complexity. In a closed-loop system, the algorithms adapt in both real-time — during gameplay — and between treatment sessions to automatically adjust the level — or dose — for a personalised treatment adapted to the needs of each individual patient.

After their first treatment period, children showed reductions in impairment of their daily activities and of ADHD symptoms, as well as remaining stable between treatments, and then improved again after a second treatment.

(To be continued…)

Your responses and feedback are welcome!

Source: “Effectiveness of a digital therapeutic as adjunct to treatment with medication in pediatric ADHD,” Nature.com, 03/26/21
Source: “Akili presents more positive trial data for ADHD gaming therapy,” ClinicalTrialsArena.com, 03/29/21
Image by u_atk62mjqnp!/Pixabay

Leave a Reply

Your email address will not be published. Required fields are marked *

FAQs and Media Requests: Click here…

Profiles: Kids Struggling with Weight

Profiles: Kids Struggling with Obesity top bottom

The Book

OVERWEIGHT: What Kids Say explores the obesity problem from the often-overlooked perspective of children struggling with being overweight.

About Dr. Robert A. Pretlow

Dr. Robert A. Pretlow is a pediatrician and childhood obesity specialist. He has been researching and spreading awareness on the childhood obesity epidemic in the US for more than a decade.
You can contact Dr. Pretlow at:

Presentations

Dr. Pretlow’s invited presentation at the American Society of Animal Science 2020 Conference
What’s Causing Obesity in Companion Animals and What Can We Do About It

Dr. Pretlow’s invited presentation at the World Obesity Federation 2019 Conference:
Food/Eating Addiction and the Displacement Mechanism

Dr. Pretlow’s Multi-Center Clinical Trial Kick-off Speech 2018:
Obesity: Tackling the Root Cause

Dr. Pretlow’s 2017 Workshop on
Treatment of Obesity Using the Addiction Model

Dr. Pretlow’s invited presentation for
TEC and UNC 2016

Dr. Pretlow’s invited presentation at the 2015 Obesity Summit in London, UK.

Dr. Pretlow’s invited keynote at the 2014 European Childhood Obesity Group Congress in Salzburg, Austria.

Dr. Pretlow’s presentation at the 2013 European Congress on Obesity in Liverpool, UK.

Dr. Pretlow’s presentation at the 2011 International Conference on Childhood Obesity in Lisbon, Portugal.

Dr. Pretlow’s presentation at the 2010 Uniting Against Childhood Obesity Conference in Houston, TX.

Food & Health Resources